Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients.

Clark, Gary M.; Mathieu, M.; Owens, Marilyn A.; Dressler, Lynn G.; Eudey, L; Tormey, Douglass C.; Osborne, C. Kent; Gilchrist, Kennedy W.; Mansour, Edward G.; Abeloff, Martin D.

doi:10.1200/jco.1992.10.3.428

Cited by 111 publications

(36 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer patients with low S-phase fraction (a measure of proliferative action) had significantly longer disease-free survival compared with patients with high S-phase fractions (P = 0.0008; ref. 18). Differences in the distribution of S-phase fraction by race were reported by Elledge et al (13).…”

Section: Tumor Biologymentioning

confidence: 77%

Breast Cancer in African-American Women: Differences in Tumor Biology from European-American Women

Hicks²,

2006

View full text Add to dashboard Cite

Disparities exist between African-American and EuropeanAmerican women in the incidence and nature of breast cancer. African-American women are more often diagnosed with breast cancer at an earlier age and with more aggressive disease, characterized by higher grade and negative estrogen and progesterone receptor status. Recent findings reveal specific gene expression patterns associated with the more aggressive breast cancers observed in African-American women. An overview of the current literature about racial differences in breast cancer prompts questions for future research to elucidate causes for the apparent disparities in tumor biology. (Cancer Res 2006; 66(17): 8327-30) EpidemiologyBreast cancer is the most common cancer diagnosed among women in the United States, with >130,000 cases diagnosed yearly. The Surveillance, Epidemiology, and End Results (SEER) database, a large population-based database, has shown that breast cancer incidence and mortality rates have differed between AfricanAmerican and European-American women over the past 2 decades (1). Between 1998 and 2002, European-American women had higher age-adjusted breast cancer incidence rates compared with African-American women (143 per 100,000 versus 119 per 100,00; ref. 1). Among women ages z50 years, European Americans were at a greater risk for developing the disease compared with AfricanAmerican women (397 per 100,000 versus 323 per 100,000), but the pattern was reversed among women ages <35 years. For each age group <35 years, incidence rates were higher among African-American women. Furthermore, compared with EuropeanAmerican women, African-American women have the highest age-adjusted mortality rates from the disease. Between 1995 and 2001, the 5-year survival rate from breast cancer was 75.9% for African-American women and 89.5% for European-American women, with age-specific breast cancer mortality rates among younger African-American women approximately twice that of younger European-American women (1).It has been suggested that higher mortality and lower survival rates among African-American women are due to factors associated with lower socioeconomic status and later stage at diagnosis (2-5). However, in several studies, racial differences in survival remained after adjustment for stage at diagnosis, access to health care, treatment, comorbid illness, marital status, and other pathologic and sociodemographic variables (4, 6-9). These data point to possible differences in the nature of the disease itself, supported by the observation that breast cancer in AfricanAmerican women is more aggressive at presentation, characterized by an increased prevalence of high-grade, hormone receptornegative tumors as shown in Table 1. In this article, we review the current literature about breast cancer in African-American women, with a focus on tumor biology, particularly in comparison with breast cancer in European-American women. Tumor BiologyTumor grade. African-American women are more likely to be diagnosed with high-grade disease compar...

show abstract

Section: Tumor Biologymentioning

confidence: 77%

Breast Cancer in African-American Women: Differences in Tumor Biology from European-American Women

Hicks²,

2006

View full text Add to dashboard Cite

show abstract

“…Both node-negative and node-positive breast cancer patients contain identifiable subgroups with greatly different prognosis (Hedley et al, 1987;Sigurdsson et al, 1990;Ewers et al, 1991;Clark et al, 1992;Joensuu and Toikkanen, 1992). Evidence from a large number of studies indicates an association between high Sphase fraction (SPF) and a shorter disease-free survival and overall survival of patients with breast cancer (Hedley et al, 1987;Kallioniemi et al, 1988;StAl et al, 1989;Toikkanen et al, 1989;Uyterlinde et al, 1990;Ewers et al, 1991;Joensuu and Toikkanen, 1992;O'Reilly et al, 1992;Clark et al, 1993).…”

mentioning

confidence: 99%

Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?

Hietanen

Blomqvist²,

Wasenius³

et al. 1995

Br J Cancer

View full text Add to dashboard Cite

The relationship between the response to chemotherapy with cyclophosphamide, epirubicin and fluorouracil as well as the time to progression of metastasised breast cancer and DNA ploidy and S-phase fraction (SPF) of primary tumours was examined using paraffin-embedded tumour tissue from 81 patients. The response to chemotherapy was significantly better in patients with tumours with a high SPF, and in addition the time to progression was longer in the high-SPF group. There was no significant difference when the DNA ploidy and response to treatment were compared.

show abstract

“…It is also free from all encumbrances of karyotyping such as a small number of recognizable metaphases, minimal chromosome spreading, poor banding quality and condensed or fuzzy appearance of chromosome. SPF has been studied in a number of hematological diseases including MDS and solid tumors for the purpose of classifi cation, grading and prognosis [15][16][17][18][19][20][21].…”

Section: Discussionmentioning

confidence: 99%

“…Flow cytometric analysis of S-phase fraction (SPF) and aneuploidy have been studied in different hematological malignancies including myelodysplastic syndrome [15,16], chronic myeloid leukemia [17], acute myeloid leukemia [18], non-Hodgkin's lymphoma [19] as well as in solid tumors such as prostate cancer [20] and breast cancer [21] for the purpose of classifi cation, grading and prognosis. DNA histograms obtained by fl ow cytometry (FCM) provide two functional factors i.e.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic values of S-phase fraction and aneuploidy in patients with bone marrow aplasia

Tripathi

Tripathi²,

Kumar³

et al. 2009

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Aim It is often diffi cult and challenging task to differentiate aplastic anemia (AA) from hypoplastic myelodysplastic syndrome (HMDS) among the patients with bone marrow aplasia. This is possibly because of the considerable clinical, cytological and histological similarities between these two disorders. As prognostic and therapeutic approach to AA and HMDS are different, it is imperative to differentiate them at the time of initial diagnosis. Various attempts have been made in the past to differentiate AA from HMDS. In the present study, we explored the value of certain new parameters i.e. S-phase fraction (SPF) and aneuploidy that could be used for this purpose. Materials and methodsThe study included 46 consecutive patients with aplastic anemia, 15 patients with HMDS along with 32 age and sex-matched control subjects. Sphase fraction and aneuploidy analysis was carried out by fl ow cytometry using Mod Fit-LT V3.0 software. ResultsThe mean SPF value was signifi cantly lower (p=0.02) in patients with AA and higher (p=0.01) in HMDS as compared to that of the control. Aneuploidy was present in 15.2% patients with AA and in 33.3% HMDS cases. During follow-up, 4 patients with AA developed MDS, out of these, three patients had aneuploidy as well as high SPF value at the time of diagnosis. Two patients with HMDS who had aneuploidy and high SPF, converted into AML. Eleven patients died during the study, in whom 8 had aneuploidy and high SPF value. ConclusionWe conclude that high SPF value and presence of aneuploidy favour the diagnosis of HMDS rather than AA. SPF and aneuploidy may be important parameters in patients with AA to predict their propensity to evolve into myelodysplastic syndrome and acute myeloid leukemia. SPF value may also be useful in the early diagnosis of HMDS before morphologically evidence of dysplasia is apparent.

show abstract

Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients.

Abstract: S-phase fraction provides additional prognostic information for predicting disease-free survival for axillary node-negative breast cancer patients with small, ER-positive tumors.

Cited by 111 publications

References 14 publications

Breast Cancer in African-American Women: Differences in Tumor Biology from European-American Women

Breast Cancer in African-American Women: Differences in Tumor Biology from European-American Women

Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?

Diagnostic and prognostic values of S-phase fraction and aneuploidy in patients with bone marrow aplasia

Contact Info

Product

Resources

About